Eight patients with a diagnosis of colorectal, pancreatic, esophageal, breast, thyroid, gastric, or cholangiocarcinoma had an FGFR2 alteration and received erdafitinib or derazantinib. The gene discussed is FGFR2; the disease is cholangiocarcinoma.